Tagged with

AstraZeneca France You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a rising generics market in France and increased regulations for market authorization. How has the business changed for AstraZeneca in this…

Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings that things are moving faster while the truth is that they have always been moving at this pace! The only…

Dr. F. Köhler Chemie Your father was the founder of Dr. Franz Köhler Chemie – that carries his name – and was a very well respected doctor among the German medical and pharmaceutical community. What have been the main challenges you faced when taking over the company 25 years ago and becoming its General…

LEEM - Les Enterprises du Medicament What are the main tasks of the LEEM? The LEEM is the only professional organization representing the pharmaceutical industry in France. It includes almost all companies which seek to develop, manufacture and market drugs. Leem represents all components of the profession: international groups, medium-sized companies, an important fabric of small,…

July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within the pharmacy. Could you explain to us why it took so long in France to implement such a measure, while in most developed markets…

FPS - Facophar Santé FPS is a hundred year old organization with roots in the beginning of the last century representing today SME suppliers to the health industries. Given the variety of its membership what are the current priorities of FPS and how does the organization stay relevant to its multiple industries? Firstly I…

US pharmaceutical companies have long been in the French market but in your experience how do you feel they have integrated the differences in culture? Is this a finished topic in this industry? In France, many US companies are in reality French companies, meaning most general managers are French, and…

GEMME Generic drugs were a very late arrival for the French market in comparison with other European markets and healthcare systems on a par with the French one. Today the gap has been narrowed very quickly as highlighted by public opinion and the fact everyone knows about generic drugs, but how…

LEEM - Les Enterprises du Medicament Throughout your prolific career in the pharmaceutical industry, what would you describe have been the major changes in the French pharmaceutical market and to what extent has France kept up? I think France has kept up with the world market albeit with some notable differences, namely in terms of our…

France Biotech France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this? In fact, there were some delays in consciousness of the biotech trend. Compared to other countries, it took more time…

FEFIS represents 11 different associations across the industry with a very broad scope. How does the organization represent all of these different sectors? FEFIS represents as much as possible activities involving the health field. For many years, the organization was a sleeping association but about five years ago Jean-Pierre Cassan,…

After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is reorganizing research in France, creating many tensions. Why did you accept this position given this turbulent situation? The answer to…